Last reviewed · How we verify
H001 Capsule 200mg-qd
H001 Capsule 200mg-qd is a medication that targets the renin-angiotensin system to lower blood pressure.
H001 Capsule 200mg-qd is a medication that targets the renin-angiotensin system to lower blood pressure. Used for Hypertension.
At a glance
| Generic name | H001 Capsule 200mg-qd |
|---|---|
| Sponsor | Livzon Pharmaceutical Group Inc. |
| Drug class | ACE inhibitor |
| Target | Angiotensin-converting enzyme (ACE) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
It works by inhibiting the angiotensin-converting enzyme (ACE), which is involved in the production of angiotensin II, a potent vasoconstrictor. By blocking ACE, H001 Capsule 200mg-qd reduces the levels of angiotensin II, leading to vasodilation and a decrease in blood pressure.
Approved indications
- Hypertension
Common side effects
- Cough
- Dizziness
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- H001 Capsule 200mg-qd CI brief — competitive landscape report
- H001 Capsule 200mg-qd updates RSS · CI watch RSS
- Livzon Pharmaceutical Group Inc. portfolio CI